**Supplementary information**

**Supplementary Table 1:** Definition of variables based on ATC, ICD-8, ICD-10, and procedure codes.

|  |  |
| --- | --- |
|  | ICD-code, procedure, or ATC codes |
| Psychiatric hospital contact | ICD-10: F00-F99 |
| Depressive disorder | ICD-10: F32-F33 |
| Psychotic disorder | ICD-10: F20-29 |
| Anxiety disorder | ICD-10: F40-F41 |
| Substance abuse | ICD-10: F10-F19 |
|  |  |
| Psychopharmacological treatment |  |
| Antidepressants | ATC: N06A |
| *SSRI* | ATC: N06AB03-6, N06AB08, N06AB10 |
| *SNRI* | ATC: N06AX16, N06AX21 |
| *TCA* | ATC: N06AA02, N06AA04, N06AA09-10 |
| *Other* | ATC: N06AX03, N06AX11, N06AX18 |
| Antipsychotics | ATC: N05A |
| Lithium | ATC: N05AN01 |
| Anxiolytics | ATC: N05B |
|  |  |
|  |  |
| Commonly prescribed medication |  |
| Beta-blockers | ATC: C07 |
| Calcium channel blockers | ATC: C08 |
| Renin-angiotensin system acting agents | ATC: C09 |
| Diuretics | ATC: C03 |
| Antithrombotic agents | ATC: B01A |
| Lipid modifying agents | ATC: C10 |
| Corticosteroids | ATC: H02 |
| Anti-inflammatory agents | ATC: M01 |
| Analgesics | ATC: N02 |
| Glucose lowering drugs | ATC: A10 |
|  |  |
| Diabetes | ICD-8: 249-250, 2515.  ICD-10: E10-E15, E160-162, O24, T383A, M142, G590, G632, H280, H334, H450, H360, N083 |
|  |  |
| Microvascular complications | ICD-10: E104, E114, E144, G590, G632,  E103, E113, E143, H340-H342, H280, H334, H450, H360, H540, H541, H544, H25, H268, H269, H430, H431, H438C, H439, H334A, H330, H335, KCKC10, KCKC15, KCKD65,  E102, E112, E142, I120, N083, N06, N17-N19, R809, H340-H342 |
| Macrovascular complications | ICD-10: KFNA, KFNB, KFNC, KFND, KFNE, KFNF, KFNG, KFNH, KFNW, KFLF, KPAE+F+H+N+P+Q, KPAW99, KPAU74, KPBE+F+H+N+P+Q, KPBW, KPGH10, KPCE+F+H+N+P+Q, KPCW99, KPCW20, KPCU74+82+83+84, KPGE+F+H+N+P+Q, KPGW99, KPGW20, KPEE+F+H+N+P+Q+W, KPFE+H+N+P+Q+W, KPGH20+21+22+23+30+31+40+99, KPDU74+82+83+84, KPEU74+82+83+84, KPFU74+82+83+84, KPGU74+83+84+99, KPGW, KPWG, KAAL10, KAAL11, KNBQ, KNCQ, KNDQ, KNEQ, KNFQ, KNGQ, KNHQ  KPDE+F+H+N+P+Q  KPGW99, KPGW20  KPEW  I20-I25, T822A, T823  I61, I63-I66, I672, I678-I679, I691, I693-I698  I702, I742-I745, I739A, I739B, I739C, E105, E115,  I700, I708, I709, I740-I741, I748-I749, N280, I701, K550-K551, K558-559 |
| Obesity | ICD-10: E65, E66, E68 |
| Charlson Comorbidity index  Myocardial infarction  Congestive Heart failure  Peripheral vascular disease  Cerebrovascular disease  Dementia  Chronic pulmonary disease  Connective tissue disease  Ulcer disease  Mild liver disease  Hemiplegia  Moderate to severe renal disease  Any tumor  Leukemia  Lymphoma  Moderate to severe liver disease  Metastatic solid tumor  AIDS | ICD-10: I21-I23  ICD-10: I50, I11.0, I13.0, I13.2  ICD-10: I70-I74, I77  ICD-10: I60-I69, G45, G46  ICD-10: G30  ICD-10: J40-J47, J60-J67, J68.4, J70.1, J70.3, J84.1, J92.0, J96.1, J98.2, J98.3  ICD-10: M05, M06, M08, M09, M30-M36, D86  ICD-10: K22.1, K25-K28  ICD-10: B18; K70.0-K70.3; K70.9; K71; K73; K74; K76.0  ICD-10: G81, G82  ICD-10: I12, I13, N00-N05, N07, N11, N14, N17-N19, Q61  ICD-10: C00-C75  ICD-10: C91-C95  ICD-10: C81-C85, C88, C90, C96  ICD-10: B15.0, B16.0, B16.2, B19.0, K70.4, K72, K76.6, I85  ICD-10: C76-C80  ICD-10: B21-B24 |
| Alcohol-related disorders | ICD-10: F10, G312, G621, G721, I426, K70, K292, R780, T51, E244, L278A. |
| Smoking-related disorders | ATC: R03  ICD-10: Z587, Z720, J40, J41, J42, J43, J44, |
| Atrial fibrillation | ICD-10: I48 |
| Hyper/hypothyroidism | ICD-10: E03, E06, E05 |
| Hypertension | ICD-10: I10-I15 |
| Osteoporosis | ICD-10: M80-M82 |
| Neurological disease | ICD-10: G04-G99 |

Abbreviations: ICD=international classification of diseases. ATC=anatomical theurapeutic chemical

**Supplementary Table 2:** Use of psychopharmacological treatment (at least two prescriptions redeemeda) within the first two years after incident T2D or matched datea

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Individuals with T2D  N=56,640 (%) | | Individuals without T2D (controls)  N=315,694 (%) | |
|  | Number of individuals (%) | Incidence rate per 1000 years follow-up, (95% CI) | Number of individuals (%) | Incidence rate per 1000 years follow-up,  (95% CI) |
| **Any psychopharmacological agent** | 2,830 (5.0%) | 26.38 (25.43-27.37) | 7,835 (2.5%) | 12.65 (12.37-12.93) |
|  |  |  |  |  |
| **Antidepressants** |  |  |  |  |
| Any antidepressant | 2,155 (3.8%) | 20.09 (19.26-20.96) | 5,553 (1.8%) | 8.96 (8.73-9.20) |
| SSRI | 1,222 (2.2%) | 11.39 (10.77-12.05) | 3,091 (1.0%) | 4.99 (4.82-5.17) |
| SNRI | 174 (0.3%) | 1.62 (1.40-1.88) | 302 (0.1%) | 0.49 (0.44-0.55) |
| TCA | 351 (0.6%) | 3.27 (2.95-3.63) | 729 (0.2%) | 1.18 (1.09-1.27) |
| Other | 459 (0.8%) | 4.28 (3.90-4.69) | 1,389 (0.4%) | 2.13 (2.13-2.36) |
|  |  |  |  |  |
| **Antipsychotics** |  |  |  |  |
| Any antipsychotic | 381 (0.7%) | 3.55 (3.21-3.93) | 902 (0.3%) | 1.46 (1.36-1.55) |
|  |  |  |  |  |
| **Anxiolytics** |  |  |  |  |
| Any anxiolytic | 615 (1.1%) | 5.73 (5.30-6.20) | 2,236 (0.7%) | 3.61 (3.46-3.76) |
|  |  |  |  |  |

a Redefining the outcome to require redemption of at least two prescriptions for psychopharmacological drugs within the two years following onset of T2D/matched data

Abbreviations: T2D=type 2 diabetes, SSRI=selective serotonin reuptake inhibitor, SNRI=serotonin–norepinephrine reuptake inhibitor, TCA=tricyclic antidepressant

**Supplementary Table 3:** Propensity score matched analysis of the association between T2D and psychopharmacological treatment (at least two prescriptions redeemeda) within the first two years after incident T2D or matched date

|  |  |  |  |
| --- | --- | --- | --- |
|  | Propensity score model | | |
|  | Individuals with T2D  (n=44,742) | Propensity score matched controls without T2D  (n=44,742) | Hazard ratio (HR) |
| **Any psychopharmacological agent** | 2,105 (4.7%) | 1,335 (3.0%) | 1.63 (1.52-1.74) |
|  |  |  |  |
| **Antidepressants** |  |  |  |
| Any antidepressant | 1,598 (3.6%) | 992 (2.2%) | 1.66 (1.54-1.80) |
| SSRI | 891 (2.0%) | 504 (1.1%) | 1.82 (1.63-2.03) |
| SNRI | 127 (0.3%) | 63 (0.1%) | 2.07 (1.53-2.80) |
| TCA | 269 (0.6%) | 148 (0.3%) | 1.87 (1.53-2.28) |
| Other | 350 (0.8%) | 268 (0.6%) | 1.34 (1.14-1.57) |
|  |  |  |  |
| **Antipsychotics** |  |  |  |
| Any antipsychotic | 273 (0.6%) | 144 (0.3%) | 1.94 (1.59-2.38) |
|  |  |  |  |
| **Anxiolytics** |  |  |  |
| Any anxiolytic | 472 (1.1%) | 340 (0.8%) | 1.42 (1.24-1.64) |
|  |  |  |  |

a Redefining the outcome to require redemption of at least two prescriptions for psychopharmacological drugs within the two years following onset of T2D/matched data

Abbreviations: T2D=type 2 diabetes, SSRI=selective serotonin reuptake inhibitor, SNRI=serotonin–norepinephrine reuptake inhibitor, TCA=tricyclic antidepressant

**Supplementary Table 4:** Use of psychopharmacological treatment and psychiatric hospital contact within the first two years after incident T2D or matched date - without exclusion of individuals with psychopharmacological/psychiatric hospital treatment leading up to the date of the T2D diagnosis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Individuals with T2D  N=81,975 (%) | | Individuals without T2D (controls)  N=404,713 (%) | |
|  | Number of individuals (%) | Incidence rate per 1000 years follow-up, (95% CI) | Number of individuals (%) | Incidence rate per 1000 years follow-up,  (95% CI) |
| **Any psychopharmacological agent** | 21,748 (26.5%) | 169.91 (167.60-172.24) | 69,060 (17.1%) | 98.33 (97.59-99.07) |
|  |  |  |  |  |
| **Antidepressants** |  |  |  |  |
| Any antidepressant | 15,643 (19.1%) | 115.31 (113.48-117.17) | 44,288 (10.9%) | 60.04 (59.48-60.61) |
| SSRI | 8,745 (10.7%) | 59.94 (58.67-61.23) | 25,897 (6.4%) | 33.52 (33.52-34.35) |
| SNRI | 2,476 (3.0%) | 16.15 (15.53-16.80) | 5,003 (1.2%) | 6.35 (6.18-6.53) |
| TCA | 2,880 (3.5%) | 18.71 (18.03-19.42) | 7,020 (1.7%) | 8.87 (8.66-9.08) |
| Other | 4,374 (5.3%) | 28.73 (27.88-29.61) | 12,665 (3.1%) | 16.14 (15.86-16.43) |
|  |  |  |  |  |
| **Antipsychotics** |  |  |  |  |
| Any antipsychotic | 4,852 (5.9%) | 31.92 (31.02-32.85) | 11,686 (2.9%) | 14.80 (14.53-15.07) |
| Olanzapine | 804 (1.0%) | 5.07 (4.73-5.45) | 1,751 (0.4%) | 2.17 (2.07-2.28) |
| Quetiapine | 1,034 (1.3%) | 6.61 (6.21-7.03) | 2,082 (0.5%) | 2.61 (2.50-2.73) |
| Risperidone | 890 (1.1%) | 5.80 (5.43-6.19) | 2,251 (0.6%) | 2.86 (2.74-2.98) |
| Haloperidol | 500 (0.6%) | 3.26 (2.98-3.55) | 1,067 (0.3%) | 1.35 (1.28-1.44) |
|  |  |  |  |  |
| **Anxiolytics** |  |  |  |  |
| Any anxiolytic | 8,482 (10.3%) | 56.92 (55.92-58.18) | 31,175 (7.7%) | 41.17 (40.72-41.64) |
| Benzodiazepines | 8,153 (9.9%) | 54.53 (53.33-55.75) | 30,197 (7.5%) | 39.82 (39.37-40.27) |
|  |  |  |  |  |
|  |  |  |  |  |
| **Psychiatric hospital contact:** |  |  |  |  |
| Any contacta | 2,611 (3.2%) | 17.22 (16.57-17.90) | 8,071 (2.0%) | 10.32 (10.09-10.54) |
| Depressive disorder | 848 (1.0%) | 5.52 (5.16-5.91) | 2,444 (0.6%) | 3.10 (2.98-3.23) |
| Anxiety disorder | 174 (0.2%) | 1.14 (0.98-1.32) | 472 (0.1%) | 0.60 (0.55-0.65) |
| Psychotic disorder | 569 (0.7%) | 3.68 (3.39-4.00) | 1,101 (0.3%) | 1.39 (1.31-1.48) |
| Substance use disorder | 50 (0.1%) | 0.33 (0.25-0.44) | 210 (0.1%) | 0.28 (0.25-0.32) |

Abbreviations: T2D=type 2 diabetes, SSRI=selective serotonin reuptake inhibitor, SNRI=serotonin–norepinephrine reuptake inhibitor, TCA=tricyclic antidepressant

**Supplementary Table 5:** Incident psychopharmacological treatment and psychiatric hospital contact in the first five years after incident T2D or matched date (for the controls)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Individuals with T2D  N=44,911 (%) | | Individuals without T2D (controls)  N=249,583 (%) | |
|  | Number of individuals (%) | Incidence rate per 1000 years follow-up, (95% CI) | Number of individuals (%) | Incidence rate per 1000 years follow-up,  (95% CI) |
| **Any psychopharmacological agent** | 7,231 (16.1%) | 38.76 (37.88-39.66) | 27,127 (10.9%) | 24.16 (23.88-24.45) |
|  |  |  |  |  |
| **Antidepressants** |  |  |  |  |
| Any antidepressant | 5,098 (11.4%) | 26.76 (26.04-27.51) | 16,606 (6.7%) | 14.51 (14.29-14.72) |
| SSRI | 2,852 (6.4%) | 14.57 (14.04-15.11) | 9,230 (3.7%) | 7.95 (7.79-8.12) |
| SNRI | 442 (1.0%) | 2.19 (1.99-2.40) | 1,071 (0.4%) | 0.91 (0.85-0.96) |
| TCA | 1,115 (2.5%) | 5.58 (5.27-5.92) | 3,148 (1.3%) | 2.68 (2.59-2.78) |
| Other | 1,408 (3.1%) | 7.06 (6.71-7.44) | 4,946 (2.0%) | 4.23 (4.11-4.35) |
|  |  |  |  |  |
| **Antipsychotics** |  |  |  |  |
| Any antipsychotic | 1,101 (2.5%) | 5.49 (5.17-5.82) | 3,861 (1.5%) | 3.29 (3.19-3.39) |
| Olanzapine | 131 (0.3%) | 0.65 (0.55-0.77) | 457 (0.2%) | 0.39 (0.35-0.42) |
| Quetiapine | 167 (0.4%) | 0.83 (0.71-0.96) | 610 (0.2%) | 0.52 (0.48-0.56) |
| Risperidone | 263 (0.6%) | 1.30 (1.15-1.47) | 935 (0.4%) | 0.79 (0.74-0.85) |
| Haloperidol | 314 (0.7%) | 1.55 (1.39-1.73) | 1,011 (0.4%) | 0.86 (0.81-0.91) |
|  |  |  |  |  |
| **Anxiolytics** |  |  |  |  |
| Any anxiolytic | 2,635 (5.9%) | 13.35 (12.85-13.89) | 12,208 (4.9%) | 10.57 (10.38-10.76) |
| Benzodiazepines | 2,443 (5.4%) | 12.35 (11.87-12.85) | 11,516 (4.6%) | 9.96 (9.78-10.14) |
|  |  |  |  |  |
|  |  |  |  |  |
| **Psychiatric hospital contact:** |  |  |  |  |
| Any contacta | 885 (2.0%) | 4.42 (4.14-4.72) | 4,919 (2.0%) | 4.21 (4.09-4.33) |
| Depressive disorder | 237 (0.5%) | 1.18 (1.03-1.33) | 1,284 (0.5%) | 1.09 (1.03-1.15) |
| Anxiety disorder | 36 (0.1%) | 0.18 (0.13-0.25) | 205 (0.1%) | 0.17 (0.15-0.20) |
| Psychotic disorder | 48 (0.1%) | 0.24 (0.18-0.32) | 279 (0.1%) | 0.24 (0.21-0.27) |
| Substance use disorder | 22 (0.0%) | 0.11 (0.07-0.17) | 179 (0.1%) | 0.15 (0.13-0.18) |

Abbreviations: T2D=type 2 diabetes, SSRI=selective serotonin reuptake inhibitor, SNRI=serotonin–norepinephrine reuptake inhibitor, TCA=tricyclic antidepressant

**Supplementary Table 6:** Incident psychopharmacological treatment and psychiatric hospital contact in the first five years after incident T2D or matched date (for the propensity score matched controls)

|  |  |  |  |
| --- | --- | --- | --- |
|  | Individuals with T2D  (n=35,165) | Propensity score matched controls without T2D  (n=35,165) | Hazard ratio (HR) |
| **Any psychopharmacological agent** | 5,531 (15.7%) | 4,462 (12.7%) | 1.29 (1.24-1.35) |
|  |  |  |  |
| **Antidepressants** |  |  |  |
| Any antidepressant | 3,767 (10.7%) | 2,801 (8.0%) | 1.42 (1.35-1.49) |
| SSRI | 2,057 (5.8%) | 1,500 (4.3%) | 1.44 (1.34-1.54) |
| SNRI | 280 (0.8%) | 163 (0.5%) | 1.79 (1.48-2.17) |
| TCA | 846 (2.4%) | 568 (1.6%) | 1.55 (1.40-1.73) |
| Other | 1,010 (2.9%) | 877 (2.5%) | 1.20 (1.10-1.32) |
|  |  |  |  |
| **Antipsychotics** |  |  |  |
| Any antipsychotic | 767 (2.2%) | 629 (1.8%) | 1.27 (1.14-1.41) |
|  |  |  |  |
| **Anxiolytics** |  |  |  |
| Any anxiolytic | 1,988 (5.7%) | 1,813 (5.2%) | 1.14 (1.07-1.22) |
| Benzodiazepines | 1,841 (5.2%) | 1,701 (4.8%) | 1.13 (1.05-1.20) |
|  |  |  |  |
| **Psychiatric hospital contact** |  |  |  |
| Any contacta | 265 (0.8%) | 244 (0.7%) | 1.11 (0.94-1.32) |
|  |  |  |  |
|  |  |  |  |

a Admission, outpatient contact, psychiatric emergency room contact.

Abbreviations: T2D=type 2 diabetes, SSRI=selective serotonin reuptake inhibitor, SNRI=serotonin–norepinephrine reuptake inhibitor, TCA=tricyclic antidepressant

**Supplementary Table 7:** Association between baseline characteristics and initiation of psychopharmacological treatment/psychiatric hospital contact during the 5-year follow-up.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Psychopharmacological treatment initiation | | Psychiatric hospital contact | |
|  | Unadjusted HRR | Fully adjusted HRRa | Unadjusted HRR | Fully adjusted HRRa |
|  |  |  |  |  |
| Age |  |  |  |  |
| <=50 | 1.00 | 1.00 | 1.00 | 1.00 |
| 51-60 | 0.85 (0.79-0.93) | 0.81 (0.74-0.88) | 0.35 (0.27-0.45) | 0.36 (0.28-0.47) |
| 61-70 | 0.88 (0.81-0.94) | 0.78 (0.72-0.85) | 0.29 (0.23-0.37) | 0.30 (0.23-0.39) |
| 71-80 | 1.37 (1.27-1.48) | 1.15 (1.05-1.25) | 0.96 (0.79-1.16) | 1.02 (0.82-1.28) |
| >80 | 1.85 (1.70-2.00) | 1.39 (1.25-1.55) | 2.18 (1.81-2.63) | 2.14 (1.65-2.77) |
|  |  |  |  |  |
| Sex |  |  |  |  |
| Female | 1.00 | 1.00 | 1.00 | 1.00 |
| Male | 0.91 (0.86-0.95) | 0.95 (0.90-1.00) | 0.84 (0.74-0.96) | 0.96 (0.83-1.11) |
|  |  |  |  |  |
| Hba1c |  |  |  |  |
| 6.5-7% | 1.00 | 1.00 | 1.00 | 1.00 |
| 7.1-7.5% | 1.06 (0.98-1.16) | 1.10 (1.02-1.19) | 0.96 (0.77-1.19) | 1.00 (0.80-1.24) |
| 7.6-8.5% | 1.05 (0.98-1.14) | 1.13 (1.05-1.23) | 1.09 (0.88-1.36) | 1.09 (0.86-1.38) |
| 8.6-9.5% | 0.93 (0.83-1.03) | 1.04 (0.93-1.17) | 0.83 (0.61-1.14) | 0.87 (0.62-1.21) |
| 9.6-10.5% | 0.91 (0.81-1.02) | 1.07 (0.95-1.20) | 0.82 (0.58-1.15) | 0.88 (0.62-1.25) |
| >10.5% | 0.84 (0.78-0.91) | 0.98 (0.90-1.06) | 0.80 (0.64-1.01) | 0.78 (0.61-1.01) |
|  |  |  |  |  |
| Charlsons Comorbidity Index |  |  |  |  |
| 0 | 1.00 | 1.00 | 1.00 | 1.00 |
| 1 | 1.34 (1.27-1.41) | 1.16 (1.09-1.24) | 1.32 (1.13-1.54) | 1.18 (0.99-1.42) |
| 2 | 1.92 (1.80-2.04) | 1.43 (1.32-1.56) | 1.68 (1.40-2.03) | 1.42 (1.11-1.81) |
|  |  |  |  |  |
| Macrovascular complications | 1.46 (1.39-1.54) | 1.16 (1.08-1.24) | 1.32 (1.13-1.54) | 1.01 (0.83-1.24) |
| Microvascular complications |  |  |  |  |
| Overall | 1.58 (1.48-1.70) | 1.11 (1.03-1.24) | 1.99 (1.66-2.39) | 1.14 (0.93-1.40) |
| Eye | 1.57 (1.45-1.69) |  | 2.05 (1.69-2.48) |  |
| Renal | 1.55 (1.32-1.81) |  | 1.27 (0.78-2.09) |  |
|  |  |  |  |  |
| Atrial fibrillation | 1.41 (1.30-1.52) | 1.00 (0.92-1.09) | 1.40 (1.13-1.75) | 0.85 (0.67-1.09) |
| Obesity | 0.94 (0.85-1.04) | 0.98 (0.88-1.09) | 1.07 (0.81-1.42) | 1.27 (0.94-1.70) |
| Alcohol-related disorder | 1.66 (1.44-1.92) | 1.60 (1.36-1.87) | 2.09 (1.44-3.03) | 2.31 (1.52-3.53) |
| Smoking-related disorderb | 1.47 (1.39-1.56) | 1.24 (1.16-1.32) | 0.93 (0.76-1.13) | 0.79 (0.64-0.98) |
|  |  |  |  |  |
| Marital status |  |  |  |  |
| Married/partner | 1.00 | 1.00 | 1.00 | 1.00 |
| Unmarried | 0.66 (0.59-0.73) | 0.69 (0.62-0.77) | 1.10 (0.85-1.42) | 1.00 (0.77-1.32) |
| Divorced/ended partnership | 1.26 (1.16-1.37) | 1.22 (1.12-1.33) | 1.29 (1.01-1.66) | 1.36 (1.06-1.75) |
| Widow | 1.75 (1.64-1.87) | 1.23 (1.14-1.33) | 2.85 (2.41-3.37) | 1.39 (1.14-1.70) |
|  |  |  |  |  |
| Commonly prescribed medication usec |  |  |  |  |
| None | 1.00 | 1.00 | 1.00 | 1.00 |
| One | 1.11 (1.03-1.20) | 0.98 (0.90-1.07) | 0.87 (0.70-1.08) | 0.72 (0.57-0.91) |
| Two | 1.16 (1.10-1.22) | 0.89 (0.83-0.96) | 0.95 (0.83-1.10) | 0.68 (0.57-0.82) |

a Adjusted for age, sex, baseline hba1c, CCI-score, obesity, smoking related disorders, alcohol related diagnoses, marital status, commonly prescribed medication use, macro- and microvascular complications

b Having been registered with a smoking-related diagnosis (see Supplementary Table 1) or having redeemed a prescription for COPD medication and/or asthma inhalers  
c Including beta-blockers, calcium channel blockers, renin-angiotensin system acting agents, lipid modifying agents, diuretics, and antithrombotic agents.